#Switzerland #Heart Failure #Zug #Berlin Heals #CMIC Therapy

Berlin Heals Holding AG: A New Dawn for Heart Failure Treatment

Berlin Heals Holding AG, a cutting-edge company in the field of medical devices, recently announced a significant achievement in their mission to revolutionize the care of heart failure. They have completed enrollment in the First-In-Human (FIH) CMIC-III clinical study, which focuses on a less invasive approach to implanting the innovative CMIC device.

The aim of this study is to assess the safety and effectiveness of the Cardiac Microcurrent (CMIC) therapy, which has shown promise in previous trials. This therapy uses a fully implantable device that generates a constant microcurrent, delivered directly to the heart to reduce inflammation and improve cardiac function. Unlike the first-generation device that required a surgical procedure, the new method can be performed in a catheterization lab and allows cardiologists to implant the device with just conscious sedation, significantly improving patient comfort and accessibility.

According to John Brumfield, the CEO of Berlin Heals, finishing the enrollment within a mere six months since the first patient was treated signifies a pivotal milestone for the company. "This reflects the overwhelming need for innovative treatment options among heart failure patients," he stated, expressing gratitude toward the patients who participated, as well as their families and the research teams.

The CMIC-III study aims to present topline data at a major cardiology congress in 2026, providing essential insights into the future of heart failure treatment. The excitement surrounding this research stems from encouraging results seen in earlier studies involving CMIC therapy, indicating its potential to transform heart failure management.

Stefan Anker, a prominent professor at Charite, Berlin, and senior author of related research, highlighted the importance of this less invasive approach. He emphasized that if the CMIC-III study can replicate the favorable outcomes observed in previous trials, this therapeutic method could vastly benefit a larger patient population.

The Challenge of Heart Failure

Heart failure is a serious condition affecting approximately 64 million people globally. It occurs when the heart's ability to pump blood is compromised, resulting in symptoms such as shortness of breath, fatigue, and decreased ability to perform everyday activities. The progressive nature of this disease leads to frequent hospitalizations and contributes to alarming mortality rates, which surpass those of many cancers. Despite its prevalence and the profound impact on quality of life, a comprehensive cure remains unavailable.

Understanding the urgent need for effective solutions, Berlin Heals Holding AG is navigating through the complexities of medical approvals. Leveraging the FDA’s Breakthrough and TAP programs, the company is planning to pursue a pivotal Investigational Device Exemption (IDE) trial to secure the necessary regulatory and reimbursement approvals for market launch.

The Future of CMIC Therapy

What distinguishes the CMIC therapy is not just its innovative technology, but also its potential for making significant advances in the treatment landscape for heart failure. The company’s commitment to expanding the scope of this device entails further studies aimed at exploring additional indications and enhancing the evidence base. Such scalability could transform the treatment paradigm for the millions affected by this debilitating condition.

As Berlin Heals moves forward, the anticipation for the results of the FIH CMIC-III study resonates across the medical community. With a dedication to improving patient outcomes and addressing unmet medical needs, the company stands at the forefront of changing the narrative around heart failure therapies, offering hope to countless individuals worldwide.